IPO - GH Research PLC

Form Type: 424B5

Filing Date: 2025-02-05

Corporate Action: Ipo

Type: New

Accession Number: 000114036125003183

Filing Summary: GH Research PLC is offering 10,000,000 ordinary shares at a public offering price of $15.00 each, totaling $150 million. As of February 4, 2025, the shares were priced at $16.32 on Nasdaq, where they are listed under the symbol 'GHRS'. Underwriting discounts amount to $9 million, resulting in expected proceeds of $141 million before expenses. The underwriters have a 30-day option to purchase an additional 1,500,000 shares. The net proceeds will be used for research, clinical development of product candidates, and general corporate purposes. Recent advancements include positive Phase 2b trial results for GH001, targeting treatment-resistant depression, which met primary endpoints with significant efficacy reported. The shares are scheduled for delivery on February 6, 2025, and investors are cautioned about risks associated with the offering and possible future volatility in share prices.

Document Link: View Document

Form Type: 424B5

Filing Date: 2025-02-03

Corporate Action: Ipo

Type: New

Accession Number: 000114036125002892

Filing Summary: GH Research PLC is offering $150 million of ordinary shares with a nominal value of $0.025 per share, as detailed in the prospectus supplement filed on February 3, 2025. The shares are listed on the Nasdaq Global Market under the symbol 'GHRS'. The last reported sale price of the ordinary shares was $10.60 as of January 31, 2025. A primary endpoint was met in their ongoing Phase 2b clinical trial for GH001, aimed at treating treatment-resistant depression (TRD), illustrating the potential for significant clinical benefits as indicated by results from various scales used in the study. There were no reported serious adverse events, and safety analysis of the study reports no significant concerns. The offering includes an option for underwriters to purchase additional shares, and the disclosed use of proceeds suggests investments in research, clinical development, and general corporate purposes.

Document Link: View Document